Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Spyre Therapeutics Inc (NASDAQ: SYRE) was $22.19 for the day, up 5.67% from the previous closing price of $21.0. In other words, the price has increased by $5.67 from its previous closing price. On the day, 2.53 million shares were traded. SYRE stock price reached its highest trading level at $22.3 during the session, while it also had its lowest trading level at $21.01.
Ratios:
Our analysis of SYRE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.49 and its Current Ratio is at 6.49. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on September 26, 2025, initiated with a Buy rating and assigned the stock a target price of $43.
On April 08, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $45.
On March 18, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $27.Wolfe Research initiated its Outperform rating on March 18, 2025, with a $27 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 02 ’25 when Burrows Scott L sold 18,428 shares for $16.26 per share. The transaction valued at 299,639 led to the insider holds 97,994 shares of the business.
Albers Jeffrey W. sold 6,700 shares of SYRE for $246,313 on Nov 06 ’24. The Director now owns 27,360 shares after completing the transaction at $36.76 per share. On Oct 25 ’24, another insider, Albers Jeffrey W., who serves as the Director of the company, sold 300 shares for $36.43 each. As a result, the insider received 10,929 and left with 34,060 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SYRE now has a Market Capitalization of 1340297344 and an Enterprise Value of 969537280.
Stock Price History:
The Beta on a monthly basis for SYRE is 2.93, which has changed by -0.35897434 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, SYRE has reached a high of $40.26, while it has fallen to a 52-week low of $10.91. The 50-Day Moving Average of the stock is 32.97%, while the 200-Day Moving Average is calculated to be 27.53%.
Shares Statistics:
SYRE traded an average of 684.56K shares per day over the past three months and 1372320 shares per day over the past ten days. A total of 60.74M shares are outstanding, with a floating share count of 51.03M. Insiders hold about 15.51% of the company’s shares, while institutions hold 99.42% stake in the company. Shares short for SYRE as of 1759190400 were 14459688 with a Short Ratio of 21.12, compared to 1756425600 on 14087087. Therefore, it implies a Short% of Shares Outstanding of 14459688 and a Short% of Float of 30.73.
Earnings Estimates
As of right now, 10.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.85, with high estimates of -$0.58 and low estimates of -$1.51.
Analysts are recommending an EPS of between -$1.99 and -$3.5 for the fiscal current year, implying an average EPS of -$2.78. EPS for the following year is -$3.12, with 10.0 analysts recommending between -$2.36 and -$4.2.
